Ocular drug delivery solutions
Precision delivery, improved adherence and enhanced patient outcomes
Delivering therapeutics to the eye presents unique challenges - from the precision required to target micro-scale anatomy to the human factors that influence real-world use. At TTP, we design ocular drug delivery systems that solve these challenges head-on. Whether it’s improving front-of-eye adherence or engineering delivery to the posterior segment, our multidisciplinary teams combine deep technical insight with creative problem-solving to accelerate development and enable better clinical and commercial outcomes.
Developing next-generation devices for the front and back of the eye
TTP has supported clients across every aspect of intra-ocular drug delivery - from topical sprays and preservative-free droppers to suprachoroidal, subretinal and intravitreal delivery systems.
Our experts in engineering, optics, fluidics and usability design work together to develop safe, effective, and manufacturable devices for even the most demanding therapies and procedures.
We support everything from early concept creation to scale-up and manufacture, helping clients navigate complex IP landscapes, overcome surgical delivery hurdles, and develop sustained-release systems that are intuitive for clinicians and patients alike.
Solving complex challenges in ophthalmic delivery
From front-of-eye adherence issues to precision delivery at the back of the eye, we tackle the technical challenges that can derail ocular drug delivery systems. Our multidisciplinary approach enables smarter, more reliable solutions, whatever the route, formulation, or user need. Whether developing tools for surgical access, solving anatomical constraints, or ensuring devices can be scaled for manufacture, we specialise in addressing the intricacies of advanced ophthalmic delivery.
Intravitreal delivery systems
We’ve developed implant inserters and sustained-release delivery tools that solve challenges in retention, placement, and visualisation- bringing confidence to posterior segment delivery.
Suprachoroidal and subretinal access
Our team has tackled anatomical, mechanical, and procedural challenges to enable precise, less invasive delivery routes for advanced therapeutics like gene therapies.
Design for manufacturability and scale
Whether it’s a high-volume eye-dropper or a niche implant system, we develop devices with commercialisation in mind from day one, de-risking the path to market.
Patient-centred innovation in intra-ocular drug delivery
From improving adherence to simplifying treatment, we design delivery systems that revolve around real patient needs and behaviours. We tackle the human challenges that often derail front-of-eye treatments, from poor compliance to usability concerns, by integrating behavioural insight, user-centric design, and connected technologies. The result: smarter, easier-to-use delivery solutions that improve outcomes in the real world.
Topical delivery innovation
From preservative-free multidose systems to horizontal spray technologies, we’re redefining what’s possible beyond the dropper bottle -improving usability, adherence, and accuracy for patients.
Adherence support technologies
Low adherence remains a major barrier in eyecare. Our proprietary frameworks help design devices that integrate user support, behavioural insights, and digital connectivity to improve outcomes.
Sustained-release and implantable systems
From novel process development for sustained release technologies, to device feasibility assessments, we engineer systems to deliver drugs over weeks or months - balancing dose accuracy, surgical integration, and manufacturability.
Refining microinjection precision for subretinal gene therapy
Gyroscope/ Novartis approached TTP to enhance fluidic control in their Orbit SDS™ device, which enables precise subretinal therapy delivery for conditions like dry AMD.
Leveraging our expertise in microfluidics, tolerance analysis, and manufacturing, we developed and evaluated new component concepts within the device’s tight spatial constraints.
TTP rapidly prototyped and tested these solutions - minimising iteration cycles and simulating final moulded parts.
Our work provided the confidence Gyroscope needed to progress to manufacture, helping them achieve more consistent dosing performance in a high-stakes therapeutic context.
Advancing sustained intravitreal delivery with Ripple Therapeutics
To support Ripple Therapeutics’ novel pro-drug implants for sustained intraocular delivery, TTP rapidly developed and evaluated new concepts to secure and safely release delicate implants via intravitreal injectors.
Our team explored solutions compatible with implants as thin as a human hair, helping Ripple make confident early-stage decisions. As the volume of eye injections grows, ease-of-use and reliability are becoming key differentiators.
TTP’s input helped de-risk core delivery mechanisms and lay the groundwork for future development, improving outcomes for patients and reducing burden on healthcare systems.
How we can help
Our approach and capabilities
We deliver across the entire life of a project, from opportunity discovery to production engineering. Discover how our interdisciplinary teams of experts collaborate to tackle the toughest product development challenges.
Our campus and facilities
Our award-winning campus has been designed with a clear vision. To create a space which can support our people and our clients as we develop and deliver the very best technology solutions.
Meet some of the team
Matthew Parker
Benjamin Hatton
David Cottenden
